Johnson & Johnson 8-K
Leadership change
Tom Cavanaugh will succeed retiring Jennifer Taubert as Innovative Medicine head and join the Executive Committee.
Filed 2026-08-04 08:48 ET
- 5.02 Officer/director change
- 9.01 Financial Statements and Exhibits
Summary
Innovative Medicine leadership succession. Jennifer Taubert will retire as Executive Vice President and Worldwide Chairman, Innovative Medicine, effective 9/1/2026. Tom Cavanaugh, currently Company Group Chairman, North America, Innovative Medicine, will succeed her and join the Executive Committee on that date.
Key Figures
- Innovative Medicine grew to more than $60B in annual revenue under Taubert’s leadership.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3